首页> 外文OA文献 >OCCURRENCE OF POST-INJECTION DELIRIUM/SEDATION SYNDROME AFTER APPLICATION OF OLANZAPINE LONG-ACTING INJECTION DURING ONE YEAR PERIOD
【2h】

OCCURRENCE OF POST-INJECTION DELIRIUM/SEDATION SYNDROME AFTER APPLICATION OF OLANZAPINE LONG-ACTING INJECTION DURING ONE YEAR PERIOD

机译:一年内应用奥氮嗪长效注射后注射后妄想/镇静综合症的发生

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction: The aim was to report the occurrence of after application of olanzapine long-acting injection (OLAI) in patients with schizophrenia during one year period.Subjects and methods: During one year period, OLAI was applied to 30 patients with schizophrenia (18 men, 12 women) who were non-adherent to previous treatment with oral olanzapine. Patients were 20-58 years of age (39 years old on average), diagnosed with SCID based on DSM-IV-TR criteria. Patients received OLAI in dosage between 210-405 mg (287±62 (mean ± SD)) every 2-4 weeks.Results: Out of 30 patients that received OLAI, 29 patients improved significantly without side-effects, and one patient developed post-injection delirium/sedation syndrome (PDSS). The patient\u27s somatic condition stabilized and treatment with OLAI was discontinued due to the PDSS.Conclusion: The occurrence of PDSS is not common and when it occurs, in our experience, it was reversible.
机译:前言:目的是报告奥氮平长效注射剂(OLAI)在精神分裂症患者中一年后的发生情况。研究对象和方法:一年期间,OLAI用于30例精神分裂症患者(18名男性) ,包括12名妇女),他们之前不曾接受口服奥氮平治疗。根据DSM-IV-TR标准诊断为SCID的患者年龄为20-58岁(平均39岁)。患者每2-4周接受OLAI剂量在210-405 mg(287±62(平均值±SD))之间。结果:30例接受OLAI的患者中,有29例显着改善而无副作用,其中1例在术后出现-注射del妄/镇静综合症(PDSS)。由于PDSS,患者的身体状况稳定并且停止了OLAI治疗。结论:PDSS的发生并不常见,并且根据我们的经验,它是可逆的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号